Arecor和Ligand Pharmaceuticals签署价值高达1100万美元的AT 220和AT 292版税和技术准入协议

Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million

• AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) systems
• Arecor and Sequel Med Tech, LLC to commit up to $1.3 million each to fund development work in preparation for pivotal Phase 2 trial for AT278-Insulin Pump programme
• Strategic intent is to progress to a broader co-development and commercialisation partnership for Phase 2 trial and beyond
• Non-dilutive funds raised through the monetisation of Arecor's royalty rights related to AT220 and milestone and technology access fees related to AT292
• Cash runway extended to 1H 2027